MEDICAMENT FOR TREATMENT OF COVID-19
The invention relates to a medicament for treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b. identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Similarly, the invention also relates to a vaccine comprising one or more agents interacting with at least one region of at least 4 consecutive amino acids present in the SARS-CoV-2 proteome, not conserved between the SARS-CoV-2 proteome and the human proteome..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 29. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KHAN NISAR AHMED [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2023-06-15, Last updated: 2023-06-23 |
|---|
| Patentnummer: |
EP3928783 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017205360 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017205360 | ||
| 003 | DE-627 | ||
| 005 | 20230623180058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230616s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017205360 | ||
| 035 | |a (EPA)EP3928783 | ||
| 035 | |a (EPA)71143605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KHAN NISAR AHMED |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MEDICAMENT FOR TREATMENT OF COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-29, Last update posted on www.tib.eu: 2023-06-15, Last updated: 2023-06-23 | ||
| 520 | |a The invention relates to a medicament for treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b. identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Similarly, the invention also relates to a vaccine comprising one or more agents interacting with at least one region of at least 4 consecutive amino acids present in the SARS-CoV-2 proteome, not conserved between the SARS-CoV-2 proteome and the human proteome. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BENNER ROBBERT |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71143605/publication/EP3928783A1?q=EP3928783 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 29 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 29 |c 12 | ||